Previous 10 | Next 10 |
VALENCIA, SPAIN, Sept. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of hea...
Zenosense’s (OTC: ZENO) MIDS Cardiac™ may prove revolutionary in the niche cardiac diagnostic testing market, currently valued between $2 and $6 billion in the U.S. A recent article discussing this, reads “MIDS Cardiac™ is unique, because the technology is being dev...
The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden sta...
Zenosense (OTC: ZENO), through the development of MIDS Cardiac™, seeks to provide a technology that delivers laboratory-level accuracy at the point of care. An article discussing the company’s recent success reads: “A successful development of MIDS Cardiac is just the firs...
Handheld technology platform in development to deliver high sensitivity, laboratory accuracy testing for cardiac biomarkers at the point of care Cardiac biomarker testing market expected to reach $7.2 billion this year Major potential for the patented technology to be applied to the det...
Zenosense (OTC: ZENO) is an innovative healthcare technology developer engaged in transformational, disruptive medical diagnostic projects. Recently, the company has achieved two major milestones. An article discussing the company’s recent success reads: “Health care technology c...
Zenosense (OTC: ZENO) recently reported the successful completion of a second round of testing for its MIDS Cardiac™ device, a patented handheld point-of-care (“POC”) technology for the detection of heart attack. An article discussing the device reads: “According to...
Second round of testing for MIDS Cardiac™ detection technology for cardiac emergency triage reveals breakthrough quantitative testing results American Heart Association projects that 130 million adults in the U.S. will have some form of cardiovascular disease by 2035, with total co...
Through a joint-venture ownership in MIDS Medical Ltd., Zenosense (OTC: ZENO) is developing MIDS Cardiac™, a rapid cardiac diagnostic device. An article discussing the device reads: “In the new testing, the joint venture aimed to magnetically detect assay beads below th...
Cardiovascular diseases are costing the U.S. $1 billion per day in medical fees and productivity losses The number of heart attacks is increasing on an annual basis, highlighting the importance of early detection technology Zenosense is developing a handheld device that could significan...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Desig...
VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection o...
Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold adv...